Press Release: European Medicines Agency updates treatment recommendations because of continued Fabrazyme shortage

Author (Corporate)
Series Title
Series Details EMA/CHMP/428277/2010 (6.7.10)
Publication Date 06/07/2010
Content Type

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has revised its previous recommendations on the use of Fabrazyme (agalsidase beta). This follows information from the manufacturer, Genzyme, stating that the current supply of Fabrazyme will not address the medical needs of the nearly 600 patients receiving Fabrazyme in Europe today. Fabrazyme is used to treat the rare, inherited enzyme-deficiency disorder, Fabry disease.
Source Link http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2010/07/news_detail_001046.jsp&mid=WC0b01ac058004d5c1
Related Links
EMA: Press Release: EMA/CHMP/654389/2010 (22.10.10: European Medicines Agency reviews treatment recommendations for Fabrazyme http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2010/10/WC500098370.pdf
Subject Categories
Countries / Regions